1800-272-662
Shopping Cart 0
countryflagAU
Login

Eyenovia Inc

Healthcare US EYEN

NoneUSD
-(-%)

Last update at 2025-08-04T14:08:11.628840Z

Day Range

--
LowHigh

52 Week Range

0.503.17
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap37.40M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-29.24662M
  • Revenue TTM0.00878M
  • Revenue Per Share TTM-
  • Gross Profit TTM 12.40M
  • Diluted EPS TTM-0.73

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -28.01116M -12.77839M -19.76987M -21.15676M -17.25311M
Minority interest - - - - -
Net income -27.73074M -12.99176M -19.69149M -20.98963M -17.25311M
Selling general administrative 13.53M 10.79M 7.73M 7.21M 6.14M
Selling and marketing expenses 1.20M - - - -
Gross profit 0.00000M 12.40M 1.20M - 0.00000M
Reconciled depreciation 0.31M 0.22M 0.10M 0.02M 0.02M
Ebit -26.91152M -12.90368M -19.77923M -21.32389M -17.27557M
Ebitda -26.63110M -12.85398M -19.75283M -21.30854M -17.25644M
Depreciation and amortization 0.28M 0.05M 0.03M 0.02M 0.02M
Non operating income net other - - - - -
Operating income -26.91152M -12.90368M -19.77923M -21.30854M -17.25644M
Other operating expenses 26.91M 26.90M 21.78M 21.31M 17.26M
Interest expense 1.38M 0.39M 0.02M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 0.08M 0.00252M 0.03M 0.15M 0.00334M
Net interest income -1.29673M -0.38524M 0.00936M 0.15M 0.00333M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.28042M 0.21M -0.07837M -0.16713M 0.00333M
Total revenue 0.00000M 14.00M 2.00M 0.00000M 0.00000M
Total operating expenses 26.91M 25.30M 20.98M 21.31M 17.26M
Cost of revenue 0.00000M 1.60M 0.80M - 0.00000M
Total other income expense net -1.09964M 0.13M 0.00936M 0.15M 0.00333M
Discontinued operations - - - - -
Net income from continuing ops -28.01116M -12.77839M -19.76987M -21.15676M -17.25311M
Net income applicable to common shares - -12.77839M -19.76987M -21.15676M -17.25311M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 28.78M 31.04M 31.66M 33.91M 14.70M
Intangible assets 2.12M - - - -
Earning assets - - - - -
Other current assets 0.87M 0.03M 0.73M 0.45M 0.20M
Total liab 19.78M 13.80M 11.19M 18.60M 2.96M
Total stockholder equity 9.00M 17.23M 20.47M 15.30M 11.74M
Deferred long term liab - - - 0.04M 0.05M
Other current liab 1.92M 2.25M 0.04M 0.00163M 1.33M
Common stock 0.00456M 0.00367M 0.00284M 0.00250M 0.00171M
Capital stock 0.00456M 0.00367M 0.00284M 0.00250M 0.00171M
Retained earnings -145.49156M -118.23046M -90.21931M -77.44092M -57.67105M
Other liab - - 0.02M 0.04M 0.05M
Good will - - - - -
Other assets - - 10.93M 0.12M 0.12M
Cash 14.85M 22.86M 19.46M 28.37M 14.15M
Cash and equivalents - - - - -
Total current liabilities 9.53M 4.51M 11.17M 18.20M 2.91M
Current deferred revenue 0.00000M - 2.37M 16.64M -
Net debt 1.26M -12.74022M -12.31148M -27.90847M -14.11010M
Short term debt 5.86M 0.83M 7.15M 0.10M 0.04M
Short long term debt 5.33M 0.35M 7.15M 0.10M -
Short long term debt total 16.11M 10.12M 7.15M 0.46M 0.04M
Other stockholder equity 154.49M 135.46M 110.68M 92.74M 69.41M
Property plant equipment - - 1.27M 0.40M 0.23M
Total current assets 16.45M 27.64M 22.00M 33.39M 14.35M
Long term investments - - - - -
Net tangible assets - - 20.47M 15.30M 11.74M
Short term investments - - - - -
Net receivables 0.62M 1.18M 1.81M 2.97M 0.10M
Long term debt 8.96M 8.38M - 0.37M -
Inventory 0.11M 3.57M 0.73M 1.60M -0.09523M
Accounts payable 1.75M 1.43M 1.61M 1.46M 1.54M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -0.08149M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00250M 0.00171M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -77.44092M -57.67105M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 5.17M 0.08M 8.39M 0.12M 0.12M
Deferred long term asset charges - - - - -
Non current assets total 12.33M 3.39M 9.66M 0.52M 0.35M
Capital lease obligations 1.79M 1.39M - 0.00000M 0.04M
Long term debt total - - - 0.37M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.87474M -1.61852M -0.26126M -0.16664M -0.02791M
Change to liabilities - 0.13M -0.07969M -0.22968M 2.68M
Total cashflows from investing activities - -1.61852M -0.26126M -0.16664M -0.02791M
Net borrowings - 6.79M -0.01186M -0.01186M -0.01186M
Total cash from financing activities 21.51M 21.46M 20.86M 13.51M 27.62M
Change to operating activities - -10.82807M 10.89M -0.32167M 1.24M
Net income -28.01116M -12.77839M -19.76987M -21.15676M -17.25311M
Change in cash -4.47333M -1.03498M 14.22M -5.57560M 14.48M
Begin period cash flow 27.34M 28.37M 14.15M 19.73M 5.25M
End period cash flow 22.86M 27.34M 28.37M 14.15M 19.73M
Total cash from operating activities -25.10548M -20.87443M -6.38428M -18.91931M -13.11114M
Issuance of capital stock 20.43M 12.40M 18.30M 13.21M 28.17M
Depreciation 0.31M 0.22M 0.10M 0.02M 0.02M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - -2.96604M - -
Sale purchase of stock - - 21.21M 13.77M 24.80M
Other cashflows from financing activities 9.26M 9.76M 3.04M 0.30M -0.55560M
Change to netincome - 2.32M 2.48M 2.51M 1.62M
Capital expenditures 0.87M 1.62M 0.26M 0.17M 0.03M
Change receivables - - - - -
Cash flows other operating - - 9.65M -0.06016M -0.17182M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - 14.22M -5.57560M 14.48M
Change in working capital -2.26286M -10.70195M 10.81M -0.28984M 2.51M
Stock based compensation 3.77M 2.89M 2.48M 2.51M 1.62M
Other non cash items 1.10M 0.02M 7.05M 5.03M -9.52073M
Free cash flow -25.98023M -22.49295M -6.64553M -19.08595M -13.13904M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EYEN
Eyenovia Inc		 - -% - - - 6631.83 2.79 6957.03 -1.0929
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Eyenovia Inc

295 Madison Avenue, New York, NY, United States, 10017

Key Executives

Name Title Year Born
Dr. Tsontcho Ianchulev M.D., M.P.H., MPH Co-Founder, Pres, Chief Medical Officer & Non-Exec. Chairman 1974
Mr. Michael M. Rowe CEO & Director 1962
Mr. John P. Gandolfo CPA CFO & Sec. 1961
Mr. Bren Kern Sr. VP of Manufacturing & Operations NA
Alexander Lobo Investor Contact NA
Dr. Tsontcho Ianchulev M.D., M.P.H., MPH Co-Founder & Executive Chairman 1975
Mr. John P. Gandolfo CPA CFO & Secretary 1961
Mr. Bren Kern COO & Corporate VP 1982

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.